A rapid estimation of mutation frequency in tumours would be invaluable in cancer management. Considerable evidence suggests that drug resistance in tumours frequently arises as a consequence of spontaneous somatic mutation (Goldie & Coldman, 1979) and therefore the mutation rate of a tumour will be an index of the potential to develop drug resistance. Previous studies have compared the mutation rates of cell lines using cloning assays. Cifone & Fidler (1981) reported a higher mutation rate in metastatic variant of UV-2237 fibrosarcoma cells than in a clone of the same cell line with lower metastatic potential. Warren et al. (1981) reported that fibroblasts from patients with Bloom syndrome, which predisposes individuals to various cancers, had a 10-15 fold higher mutation rate than did fibroblasts from normal individuals. These findings have been important in correlating malignant capacity with genetic instability, but unfortunately, the techniques used have limited general application since few human tumour cells will form colonies on plastic. An alternative assay, soft agar cloning, has also been used for the determination of mutation rates in a variety of mammalian cell lines, including Chinese hamster ovary cells (Li & Shimizu, 1983) and the L5178Y mouse lymphoma cell line (Irr & Snee, 1982) . Again, the low cloning efficiency of human tumour cells in soft agar (Hamburger et al., 1978) and the fact that this method selects only mutant cells which clone in agar limits the use of this assay to determine mutation frequency in human tumours. This latter source of error might bias the estimation of the mutation rate in favour of more malignant cells, which generally have higher cloning efficiencies (Elmore et al., 1983) . Morley et al. (1983) and Albertini et al. (1982) (Seshadri et al., 1984) .
We The monoclonal antibody to BrUdR was derived from the fusion of SP2/0-Agl4 cells (Shulman et al., 1978) to spleen cells from BALB/c mice immunized with bromouridine conjugated to bovine serum albumin (BSA) (K6hler & Milstein, 1975; Erlanger & Beiser, 1964) . The antibody with highest affinity and specificity for BrUdR in the DNA strand was chosen using a competitive enzyme linked immuno-sorbent assay (ELISA) (Voller et al., 1978) . Although this antibody identifies cells incorporating BrUdR after only minutes of exposure, an incubation period equivalent to one cell cycle time ensures that all cycling cells will have traversed S-phase and thus incorporated BrUdR into DNA. A fluorescence histogram of cells exposed to BrUdR for one cell cycle time is shown in Figure 1 . Superimposed on this histogram of a highly fluorescent cell population is the background fluorescence peak obtained from stained cells which had not been exposed to BrUdR. This fluorescence is identical to the autofluorescence produced by unstained cells (not shown), indicating negligible non-specific binding of the anti-BrUdR antibody.
BrUdR incorporation and subsequent fluorescent staining, was used to investigate the 6-TG dose response relationships flow cytometrically. The dose reponse curves illustrated in Figure 2 show that for CCRF-CEM cells a concentration of over 30pM6-TG for 72h is necessary to stop DNA synthesis completely in 'wild type' cells. The dose-response Relative fluorescence Figure 1 Immunofluorescent staining of proliferating cells exposed to BrUdR. CCRF-CEM cells, a human leukaemia T-cell line, growing exponentially in RPMI-1640 medium supplemented with glutamine and 10% foetal calf serum, were exposed to 10-M BrUdR for 24 h (equivalent to one cell cycle deficient in the enzyme HGPRT, is identical to that of untreated control cells under these conditions (data not shown). Figure 3 illustrates fluorescence historgrams of mutant, wild type and mixed cell populations exposed to 6TG. Histogram (A) shows that the HGPRT-1 mutants continue synthesizing DNA normally in the presence of a high concentration of 6-TG which stops DNA synthesis in the wild-type CCRF-CEM cells (B) . In the latter case there is no fluorescence peak indicating that the cells are not incorporating BrUdR. Mixtures of mutants and wild type CCRF-CEM cells in varying proportions were exposed to 6-TG in order to investigate the sensitivity of the BrUdR assay in the rapid detection of low numbers of drug-resistant cells. cycling mutant cells. The possibility of metabolic co-operation between the resistant and sensitive cells (Ochi et al., 1982) in mix experiments was examined but no evidence of this phenomenon was found. Accurate quantitation of rare cell subpopulations such as the HGPRT-cells in a mix experiment is being attempted using fluorescent beads to determine sample volume and thus cell number (Stewart & Steinkamp, 1982) . The BrUdR antibody method of identifying drug-resistant cells has many potential advantages. The method does not require high cloning efficiency conditions and provided adequate concentrations of 6-TG are used for a sufficient exposure period to kill sensitive cells, cells continuing to cycle can be assumed to be HGPRT-. As in the autoradiographic method for detection of 6-TG resistant lymphocytes described by Strauss and Albertini (1979) , cells identified as 6-TG resistant by BrUdR fluorescence cannot be proved to be mutants since they cannot be clonally expanded and the HGPRT activity measured. However Dempsey and Morley (1983) have shown, in parallel cloning and autoradiographic mutation assays in peripheral blood lymphocytes, that provided a 6-TG concentration well along the plateau of the dose-response curve is used, resistant cells measured autoradiographically usually completely lack HGPRT.
This rapid and sensitive assay can be applied in a wide range of cells. It will find an important place not only as a drug resistance assay, measuring the proportion of cells that are resistant to a chemotherapeutic agent, but also as a mutation assay measuring the rates with which tumour cells acquire drug resistance. Clearly the precise conditions for studying drug resistance in human tumours remain to the defined and currently we are using this reagent to study biopsies of xenografted tumours. The duration of drug exposure in vitro and the timing of BrUdR addition may need to be varied depending upon the cytotoxic drug being tested and the growth fraction of the tumour. A similar antibody (Gratzner, 1982) has recently been used to measure the proliferating cell fraction in vivo (Morstyn et al., 1983) and to study cell cycle perturbations (Dolbeare et al., 1983) .
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